DyLight800-1 and DyLight800-2, which have no linker between the dye and Lys-Glu urea, had much lower PSMA+ PIP tumor uptake than other compounds with linkers, confirming the importance of the linker moiety for modifying pharmacokinetics. Here, FOLH1 is linked to neoplasm.